37 completed, 6 recruiting, 3 active not recruiting, 3 terminated. 53 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 53 | Completed 37, Recruiting 6, Active not recruiting 3, Terminated 3, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
Follow dolutegravir: new trials by email Literature Review of dolutegravir trials Research Report on dolutegravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) - HIV Infections | Phase 3 | Recruiting | ViiV Healthcare | 197 | 2026-07-21 | 2026-11-13 |
| Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) - Tuberculosis, HIV | Phase 3 | Recruiting | Johns Hopkins University | 150 | 2025-09-18 | 2026-09-11 |
| Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance Dolutegravir Pill, Darunavir+Ritonavir - HIV-1-infection | Phase 3 | Recruiting | University of Nairobi | 392 | 2025-09-01 | 2025-09-11 |
| DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine - HIV-1-infection | Phase 3 | Recruiting | ANRS, Emerging Infectious Diseases | 610 | 2025-01-27 | 2026-07-27 |
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT APRETUDE (cabotegravir) 600 mg\3 mL, DAPIRING (Dapivirine) 25mg Vaginal Ring, tenofovir disoproxil and emtricitabine - HIV Infections | Phase 3 | Recruiting | Africa Health Research Institute | 2052 | 2024-02-27 | 2026-07-09 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy Dolutegravir, Lamivudine, Bictegravir - HIV, HIV Infections | Phase 3 | Active not recruiting | ViiV Healthcare | 463 | 2024-02-21 | 2026-10-14 |
| Improving HIV-1 Control in Africa With Long Acting Antiretrovirals Cabotegravir/Rilpivirine, Antiretroviral - HIV-1-infection | Phase 3 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 540 | 2022-12-08 | 2026-10-09 |
| Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch Doravirine, Dolutegravir, Triple cART regimen - HIV-1-infection | Phase 3 | Recruiting | Chelsea and Westminster NHS Foundation Trust | 150 | 2022-08-17 | 2023-10-25 |
| DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections | Phase 2 / Phase 3 | Active not recruiting | PENTA Foundation | 386 | 2022-04-22 | 2026-03-04 |
| DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women Dolutegravir plus lamivudine in a FDC - HIV Infections, Pregnancy Related | Phase 3 | Completed | Fundação Bahiana de Infectologia | 20 | 2021-07-01 | 2023-10-04 |
| Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) DOVATO - HIV-1-infection | Phase 3 | Unknown | Societa' Italiana Di Malattie Infettive E Tropicali | 440 | 2021-03-23 | 2021-07-28 |
| ANRS 12372 MODERATO Study dolutegravir, atazanavir boosted with ritonavir, tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir - HIV-1-infection | Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 480 | 2020-11-17 | 2026-10-16 |
| Nucleosides And Darunavir/Dolutegravir In Africa Darunavir, Ritonavir, Dolutegravir - Human Immunodeficiency Virus | Phase 3 | Unknown | Makerere University | 465 | 2019-07-30 | 2020-07-30 |
| Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults Dolutegravir + Lamivudine FDC - HIV Infections | Phase 3 | Completed | ViiV Healthcare | 131 | 2019-07-02 | 2021-10-21 |
| Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents DTG + 3TC FDC - HIV Infections | Phase 3 | Completed | ViiV Healthcare | 32 | 2019-05-06 | 2025-12-09 |
| Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy - HIV-1-infection | Phase 3 | Completed | NEAT ID Foundation | 140 | 2018-11-05 | 2024-12-24 |
| Dolutegravir in Pregnant HIV Mothers and Their Neonates Dolutegravir, Standard of Care (EFV + 2 NRTI backbone) - HIV-1-infection, Pregnancy Related | Phase 3 | Completed | University of Liverpool | 268 | 2018-01-22 | 2025-02-21 |
| Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate - HIV Infections | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 643 | 2018-01-19 | 2026-07-31 |
Showing 20 of 53. Sign in to see all of them.
HIV Infections (25) · Acquired Immunodeficiency Syndrome (15) · Infections (11) · Amyotrophic Lateral Sclerosis (1) · Arthralgia (1) · Breast Feeding (1) · Coinfection (1) · Osteoporosis (1) · Tuberculosis (1)
ViiV Healthcare (20) · ANRS, Emerging Infectious Diseases (4) · Fundação Bahiana de Infectologia (2) · Gilead Sciences (2) · PENTA Foundation (2) · University of Liverpool (2) · Africa Health Research Institute (1) · Babafemi Taiwo (1) · Centre Hospitalier Régional d'Orléans (1) · Chelsea and Westminster NHS Foundation Trust (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · IRCCS San Raffaele (1) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba (1) · Johns Hopkins University (1) · MRC/UVRI and LSHTM Uganda Research Unit (1)
United States (21) · France (20) · Spain (19) · Italy (16) · United Kingdom (16) · Germany (15) · South Africa (15) · Canada (13) · Russia (11) · Australia (10) · Belgium (10) · Argentina (8) · Uganda (8) · Brazil (7) · Thailand (7)
Adriano Lazzarin, Prof (1) · Alessandra Bandera, P.I. (1) · Alessandro Bartoloni, P.I. (1) · Andrea Andreoni, P.I. (1) · Annamaria Cattelan, P.I. (1) · Antonella Castagna, P.I. (1) · Antonio Cascio, P.I. (1) · Antonio Di Biagio, P.I. (1) · Babafemi Taiwo, MBBS (1)
PMID 29239893, PMID 31307948, PMID 31350995, PMID 34913844, PMID 40134635, PMID 24074642, PMID 24195548, PMID 24446523, PMID 24698485, PMID 24944232, PMID 25321146, PMID 26262777, PMID 26424673, PMID 28729158, PMID 28867499, PMID 29293895, PMID 29956087, PMID 30601976, PMID 30803969, PMID 30932951, PMID 31068270, PMID 31068272, PMID 31339676, PMID 31339677, PMID 31539371, PMID 32386721, PMID 32504574, PMID 32668455, PMID 32701823, PMID 32763217, PMID 33010240, PMID 33010241, PMID 33136751, PMID 33262331, PMID 33346335, PMID 33355914, PMID 33446115, PMID 33587500, PMID 33625064, PMID 33794181, PMID 33812487, PMID 33880558, PMID 34289276, PMID 34656207, PMID 34817414, PMID 34965338, PMID 34978890, PMID 35079789, PMID 35460601, PMID 35508986
2014 (3), 2015 (3), 2016 (3), 2017 (2), 2009 (1), 2019 (1), 2023 (1)